Conditions: Glioblastoma Multiforme; Glioma of Brain
Interventions: Drug: Ribociclib; Drug: Everolimus 2.5 MG
Sponsors: St. Joseph's Hospital and Medical Center, Phoenix; Ivy Brain Tumor Center; Barrow Neurological Institute
Recruiting
Feeds
6414 items (6414 unread) in 74 feeds
Acinar Cell Carcinoma
(36 unread)
Acinic Cell Carcinoma
(30 unread)
Adenoid Cystic Carcinoma
(95 unread)
Adrenal Gland Cancer
(568 unread)
Ampulla Of Vater
(105 unread)
Anal Cancer
(681 unread)
Angiosarcoma
(196 unread)
Appendix Cancer
(80 unread)
Bile Duct Cancer
(739 unread)
Brain and CNS
(867 unread)
Carcinoid
(278 unread)
Endocrine/Neuroendocrine
(738 unread)
Gall Bladder Cancer
(349 unread)
Hemangioendothelioma
(41 unread)
Hepatoblastoma
(123 unread)
Pancreas
(76 unread)
Phyllodes
(45 unread)
PMP and Mucinous Tumors
(63 unread)
Rhabdomyosarcoma
(237 unread)
Sarcoma
(1067 unread)
Trial - Brain Tumor (79 unread)
-
Ph0/2 Ribociclib & Everolimus
Posted: February 8th, 2019, 3:00pm GMT
-
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
Posted: February 5th, 2019, 3:00pm GMT
Condition: Primary Brain Neoplasm
Interventions: Drug: Hyperpolarized Carbon C 13 Pyruvate; Procedure: Magnetic Resonance Spectroscopic Imaging
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting -
Lidocaine and Perioperative Cytokine Levels in Blood and Cerebrospinal Fluid in Cerebral Aneurysm Patients
Posted: January 30th, 2019, 3:00pm GMT
Condition: Aneurysm, Cerebral
Intervention: Drug: Lidocaine
Sponsor: Clinical Hospital Centre Zagreb
Not yet recruiting -
Radiotherapy of Multiple Brain Metastases Using AGuIX®
Posted: January 28th, 2019, 3:00pm GMT
Conditions: Brain Metastases, Adult; Radiotherapy
Interventions: Drug: AGuIX®; Radiation: Whole Brain Radiation Therapy
Sponsors: University Hospital, Grenoble; NH THERAGUIX
Not yet recruiting -
Molecular Imaging of Pituitary Adenomas
Posted: January 24th, 2019, 3:00pm GMT
Condition: Pituitary Adenoma
Intervention: Diagnostic Test: PET imaging
Sponsors: Cardiff University; Cardiff and Vale University Health Board
Recruiting -
Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Posted: January 17th, 2019, 3:00pm GMT
Conditions: Metastatic Breast Cancer; Brain Metastases
Interventions: Drug: Nivolumab; Radiation: Stereotactic Radiosurgery
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bristol-Myers Squibb
Recruiting -
Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor
Posted: January 16th, 2019, 3:00pm GMT
Condition: Acromegaly Due to Pituitary Adenoma
Interventions: Other: GIP-A; Other: Placebo
Sponsors: University of Copenhagen; Rigshospitalet, Denmark; Aarhus University Hospital; Aalborg Universitetshospital; Odense University Hospital; Herlev and Gentofte Hospital
Not yet recruiting -
Copanlisib and Fulvestrant in Treating Postmenopausal Patients With ER+ and HER2- Metastatic Breast Cancer Progressing After Aromatase and CDK 4/6 Inhibitors Treatment
Posted: January 15th, 2019, 3:00pm GMT
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Postmenopausal; Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Drug: Copanlisib; Drug: Fulvestrant
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC
Posted: January 11th, 2019, 3:00pm GMT
Condition: NSCLC
Intervention: Drug: Apatinib
Sponsor: Hubei Cancer Hospital
Not yet recruiting -
Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC
Posted: January 10th, 2019, 3:00pm GMT
Condition: NSCLC
Interventions: Drug: Anlotinib; Drug: Docetaxel; Drug: Carboplatin
Sponsors: Tongji Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting -
Study to Evaluate Ibudilast and TMZ Combo Treatment in Recurrent GBM
Posted: December 20th, 2018, 3:00pm GMT
Conditions: Glioblastoma; Recurrent Glioblastoma; GBM; Recurrent GBM
Interventions: Drug: MN-166; Drug: Temozolomide
Sponsor: MediciNova
Recruiting -
Impact of Nasoseptal Flap Harvest Technique on Olfaction Following Endoscopic Transsphenoidal Pituitary Surgery
Posted: December 12th, 2018, 3:00pm GMT
Conditions: Pituitary Tumor; Surgery; Olfactory Nerve Injuries
Intervention: Procedure: Electrocautery versus scalpel
Sponsor: St. Michael's Hospital, Toronto
Not yet recruiting -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Posted: December 6th, 2018, 3:00pm GMT
Conditions: Cancer; Melanoma (Skin); Melanoma, Uveal; Melanoma, Ocular; Bladder Cancer; Mismatch Repair Deficiency; Microsatellite Instability; Non-melanoma Skin Cancer
Interventions: Biological: RP1; Biological: nivolumab
Sponsor: Replimune Inc.
Recruiting -
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Posted: December 5th, 2018, 3:00pm GMT
Condition: Breast Cancer
Interventions: Drug: Trastuzumab; Drug: GDC-0084
Sponsors: Dana-Farber Cancer Institute; Kazia Therapeutics Limited
Recruiting -
Wise Cortical Strip for Intraoperative Neurophysiological Monitoring
Posted: November 6th, 2018, 3:00pm GMT
Conditions: Brain Tumor Adult; Epilepsy
Intervention: Device: Wise Cortical Strip
Sponsors: Wise S.r.l.; Genae; Fondazione Don Carlo Gnocchi Onlus
Not yet recruiting -
Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases
Posted: November 6th, 2018, 3:00pm GMT
Condition: Non Small Cell Lung Cancer Metastatic
Interventions: Drug: Temozolomide capsules; Device: radiotherapy
Sponsor: Taizhou Hospital
Not yet recruiting -
Improving Brain Function After Breast Cancer Study
Posted: October 4th, 2018, 2:00pm GMT
Condition: Breast Cancer Survivors
Interventions: Behavioral: Kirtan Kriya meditation; Behavioral: Music listening program
Sponsor: University of Texas at Austin
Recruiting -
Detection of Brain Metastasis by MRI in Metastatic Colorectal Cancer Patients
Posted: October 3rd, 2018, 2:00pm GMT
Condition: Metastatic Colon Cancer
Intervention: Device: Magnetic resonance imaging
Sponsor: Poitiers University Hospital
Recruiting -
Non-invasive Glioma Characterization Through Molecular Imaging
Posted: September 25th, 2018, 2:00pm GMT
Conditions: Glioma; Brain Tumor; Primary Brain Tumor; Malignant Glioma; Malignant Primary Brain Tumor
Intervention: Diagnostic Test: 3T MRI Scanner
Sponsor: University of Miami
Recruiting -
Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases
Posted: September 21st, 2018, 2:00pm GMT
Conditions: Invasive Malignant Neoplasm; Metastatic Malignant Neoplasm in the Brain
Interventions: Procedure: Dynamic Susceptibility Contrast-MRI (DSC-MRI); Procedure: Magnetic Resonance Imaging (MRI)
Sponsor: Emory University
Recruiting -
Trial of C134 in Patients With Recurrent GBM
Posted: September 5th, 2018, 2:00pm GMT
Conditions: Glioblastoma Multiforme of Brain; Anaplastic Astrocytoma of Brain; Gliosarcoma of Brain
Intervention: Biological: C134
Sponsor: University of Alabama at Birmingham
Not yet recruiting -
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Posted: August 31st, 2018, 2:00pm GMT
Conditions: Leukemia; Brain Tumor; Solid Tumor; Lymphoma
Interventions: Drug: ALRN-6924; Drug: Cytarabine
Sponsors: Dana-Farber Cancer Institute; TeamConnor Childhood Cancer Foundation; Cookies for Kids' Cancer
Recruiting -
Awake vs. Asleep Craniotomy for Non-eloquent Gliomas
Posted: August 8th, 2018, 2:00pm GMT
Condition: Intracranial Glioma
Interventions: Procedure: Awake Anesthesia Protocol; Procedure: Non-awake Anesthesia Protocol
Sponsor: Mayo Clinic
Not yet recruiting -
Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer
Posted: August 7th, 2018, 2:00pm GMT
Condition: Breast Cancer
Interventions: Other: SAE battery; Behavioral: Assessments
Sponsors: Memorial Sloan Kettering Cancer Center; The City College of New York
Recruiting -
Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer
Posted: August 6th, 2018, 2:00pm GMT
Conditions: Metastatic Breast Cancer With HER2 Positive; Triple Negative Breast Cancer
Intervention: Procedure: Brain MRI
Sponsor: Yonsei University
Not yet recruiting -
Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis
Posted: July 19th, 2018, 2:00pm GMT
Condition: Pediatric Brain Tumor
Interventions: Procedure: Ketogenic diet; Drug: BCNU
Sponsor: Washington University School of Medicine
Not yet recruiting -
Effect of Exercise on Cancer-Related Fatigue
Posted: July 3rd, 2018, 2:00pm GMT
Conditions: Cancer-related Problem/Condition; Exercise
Interventions: Behavioral: TEHE only; Behavioral: Auricular Point Acupressure; Behavioral: Mindfulness body scan
Sponsor: Johns Hopkins University
Not yet recruiting -
Magnesium Sulphate Versus Lidocaine for Control of Emergence Hypertension
Posted: June 25th, 2018, 2:00pm GMT
Conditions: Craniotomy; Hypertension
Interventions: Drug: Magnesium sulphate; Drug: Lidocaine Hydrochloride; Drug: Normal saline
Sponsor: Ahmed Mohamed ELbadawy
Recruiting -
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors
Posted: June 21st, 2018, 2:00pm GMT
Conditions: Malignant Central Nervous System Neoplasm; Metastatic Malignant Neoplasm in the Central Nervous System
Interventions: Other: Gadolinium; Drug: Hyperpolarized Carbon C 13 Pyruvate; Procedure: Magnetic Resonance Imaging; Procedure: Magnetic Resonance Spectroscopic Imaging
Sponsor: Daniel M. Spielman
Recruiting -
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
Posted: May 24th, 2018, 2:00pm GMT
Conditions: NSCLC; Non-small Cell Lung Cancer
Intervention: Drug: Osimertinib
Sponsor: Case Comprehensive Cancer Center
Recruiting -
CB-839 With Radiation Therapy and Temozolomide in Treating Participants With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
Posted: May 18th, 2018, 2:00pm GMT
Conditions: Anaplastic Astrocytoma, IDH-Mutant; Diffuse Astrocytoma, IDH-Mutant; IDH1 Gene Mutation; IDH2 Gene Mutation
Interventions: Drug: Glutaminase Inhibitor CB-839 Hydrochloride; Other: Questionnaire Administration; Radiation: Radiation Therapy; Drug: Temozolomide
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
Posted: May 18th, 2018, 2:00pm GMT
Condition: Glioblastoma
Interventions: Drug: TN-TC11G; Drug: Temozolomide Oral Product; Radiation: Radiotherapy
Sponsors: Grupo Español de Investigación en Neurooncología; Medical Cannabis Bike Tour; Voices Against Brain Cancer; Tilray
Not yet recruiting -
Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors
Posted: May 15th, 2018, 2:00pm GMT
Conditions: Brain Neoplasms; Adult Brain Tumor
Intervention: Diagnostic Test: PET imagery
Sponsor: Center Eugene Marquis
Recruiting -
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Posted: April 9th, 2018, 2:00pm GMT
Condition: Glioblastoma
Interventions: Biological: INO-5401; Biological: INO-9012; Biological: Cemiplimab; Radiation: Radiation Therapy; Drug: Temozolomide
Sponsor: Inovio Pharmaceuticals
Recruiting -
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Posted: March 23rd, 2018, 2:00pm GMT
Conditions: Glioblastoma; Radiotherapy; Complications; Cognitive Decline; Chemoradiation
Intervention: Drug: Ramipril
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting -
Phase II Trial of Seizure Prophylaxis in Suspected Primary Glioma Patients Undergoing Craniotomy
Posted: February 16th, 2018, 3:00pm GMT
Conditions: Glioma; Glioma of Brain; Brain Tumor
Interventions: Drug: Lacosamide; Drug: Levetiracetam
Sponsor: Duke University
Recruiting -
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
Posted: February 7th, 2018, 3:00pm GMT
Condition: Newly Diagnosed High Grade Glioma
Interventions: Drug: Temozolomide; Radiation: conformal brain radiation therapy; Drug: Nivolumab; Drug: Ipilimumab; Drug: Bevacizumab; Drug: Metronomic Temozolomide
Sponsor: John Wayne Cancer Institute
Recruiting -
Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Patient Outcomes for Locally Advanced Lung and Brain Tumor Patients Treated With Proton Therapy
Posted: January 18th, 2018, 3:00pm GMT
Conditions: Lung Cancer; Brain Cancer
Interventions: Device: Siemens Somatom Definition Edge; Device: Philips Brilliance Big Bore CT/simulator
Sponsors: Washington University School of Medicine; National Cancer Institute (NCI)
Recruiting -
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
Posted: September 8th, 2017, 2:00pm GMT
Condition: Brain Tumor
Intervention: Drug: Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine
Sponsors: University of Utah; Blue Earth Diagnostics
Recruiting -
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Posted: July 25th, 2017, 2:00pm GMT
Conditions: Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma; Head and Neck Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Renal Cell Carcinoma; Gastric Cancer; Cervical Cancer; Hepatocellular Carcinoma; Microsatellite Instability; Mismatch Repair Deficiency; Colorectal Cancer
Interventions: Drug: ALT-803 + Pembrolizumab; Drug: ALT-803 + Nivolumab; Drug: ALT-803 + Atezolizumab; Drug: ALT-803 + Avelumab
Sponsor: Altor BioScience
Recruiting -
SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Contro on PD-1/PDL-1 Tx
Posted: July 18th, 2017, 2:00pm GMT
Condition: Solid Tumor
Interventions: Radiation: Stereotactic radiotherapy; Other: Biological: humanized anti-PD-1 monoclonal antibody; Other: Biological: humanized anti-PD-L1 monoclonal antibody
Sponsors: Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting -
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Posted: July 12th, 2017, 2:00pm GMT
Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Melanoma; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Skin Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Intestinal Neoplasms; Thyroid Cancer; GIST; Malignant Peripheral Nerve Sheath Tumors; Breast Secretory Carcinoma; Uterine Neoplasms; Fibrosarcoma; Infantile Fibrosarcoma; Congenital Mesoblastic Nephroma; Central Nervous System Neoplasms
Intervention: Drug: LOXO-195
Sponsors: Loxo Oncology, Inc.; Bayer
Recruiting -
Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer
Posted: June 27th, 2017, 2:00pm GMT
Conditions: Breast Adenocarcinoma; HER2/Neu Positive; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Atezolizumab; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Biological: Pertuzumab; Other: Placebo; Other: Quality-of-Life Assessment; Biological: Trastuzumab
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
Posted: June 8th, 2017, 2:00pm GMT
Conditions: 1p/19q Co-deletion; Anaplastic Astrocytoma; Diffuse Astrocytoma; Glioma; IDH1 Gene Mutation; IDH2 Gene Mutation; Oligoastrocytoma; Oligodendroglioma; WHO Grade III Glioma
Interventions: Radiation: IMRT (Intensity-Modulated Radiation Therapy); Radiation: Proton Beam Radiation Therapy; Drug: Temozolomide
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting -
Scalp Block: Hemodynamic Stability and Patient Comfort In Craniotomy Patients
Posted: June 6th, 2017, 2:00pm GMT
Conditions: Tumor, Brain; Anesthesia, Local
Interventions: Drug: Lidocaine; Drug: Sodium chloride; Drug: Bupivacaine
Sponsor: Washington University School of Medicine
Not yet recruiting -
LITT Palliative Treatment for Patients With Malignant Gliomas
Posted: June 5th, 2017, 2:00pm GMT
Conditions: Malignant Glioma of Brain; Glioblastoma
Intervention: Other: Palliative regimen consisting of LITT
Sponsors: Duke University; Monteris Medical
Recruiting -
MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma
Posted: April 11th, 2017, 2:00pm GMT
Conditions: Glioblastoma; Gliosarcoma; Recurrent Glioblastoma; TP53 wt Allele; Unmethylated MGMT Gene Promoter
Interventions: Other: Laboratory Biomarker Analysis; Drug: MDM2 Inhibitor AMG-232; Other: Pharmacological Study; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting -
Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
Posted: March 3rd, 2017, 3:00pm GMT
Condition: Pediatric Brain Tumor
Interventions: Biological: Personalized peptide vaccine; Drug: Poly ICLC; Procedure: Peripheral blood draw
Sponsor: Washington University School of Medicine
Not yet recruiting -
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Posted: February 13th, 2017, 3:00pm GMT
Conditions: Glioma; Glioblastoma; Glioblastoma Multiforme; GBM; Brain Cancer
Intervention: Drug: VAL-083 (Dianhydrogalactitol)
Sponsors: DelMar Pharmaceuticals, Inc.; Sun Yat-sen University
Recruiting -
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Posted: November 23rd, 2016, 3:00pm GMT
Conditions: EGFR Activating Mutation; EGFR NP_005219.2:p.T790M; Lung Carcinoma Metastatic in the Brain; Lung Non-Small Cell Carcinoma
Interventions: Biological: Bevacizumab; Other: Laboratory Biomarker Analysis; Drug: Osimertinib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Posted: September 21st, 2016, 2:00pm GMT
Conditions: Lymphoma; Neuroblastoma; Brain Tumor; Solid Tumor
Intervention: Drug: CUDC-907
Sponsors: Dana-Farber Cancer Institute; Curis, Inc.
Recruiting -
High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
Posted: April 1st, 2016, 2:00pm GMT
Conditions: Non-small Cell Lung Cancer; Brain Metastases
Interventions: Drug: Icotinib; Radiation: SRS; Drug: chemotherapy
Sponsor: Betta Pharmaceuticals Co., Ltd.
Recruiting -
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
Posted: March 30th, 2016, 2:00pm GMT
Conditions: Glioblastoma Multiforme; Astrocytoma, Grade III; Anaplastic Ependymoma; Clear Cell Ependymoma; Ependymoma
Interventions: Biological: Heat Shock Protein Peptide Complex-96 (HSPPC-96); Procedure: Tumor Resection; Radiation: Radiation
Sponsors: Ann & Robert H Lurie Children's Hospital of Chicago; Northwestern University
Recruiting -
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma
Posted: March 24th, 2016, 2:00pm GMT
Conditions: Glioma; Glioblastoma; Glioblastoma Multiforme; GBM; Brain Cancer
Intervention: Drug: VAL-083, Dianhydrogalactitol
Sponsor: DelMar Pharmaceuticals, Inc.
Recruiting -
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
Posted: March 23rd, 2016, 2:00pm GMT
Conditions: Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Neoplasm in the Spine; Stage IV Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Radiation: Stereotactic Radiosurgery
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Accuray Incorporated
Recruiting -
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Posted: March 16th, 2016, 2:00pm GMT
Conditions: Astrocytoma, Grade IV; Giant Cell Glioblastoma; Glioblastoma Multiforme; Gliosarcoma
Intervention: Radiation: Radiation
Sponsor: National Cancer Institute (NCI)
Recruiting -
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Posted: January 20th, 2016, 3:00pm GMT
Conditions: Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm
Interventions: Biological: Anti-LAG-3 Monoclonal Antibody BMS 986016; Biological: Anti-PD-1; Other: Pharmacological Study; Other: Laboratory Biomarker Analysis; Biological: Anti-CD137
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; National Cancer Institute (NCI); Bristol-Myers Squibb
Recruiting -
Stereotactic Radiosurgery (SRS) for Brain Metastasis
Posted: January 1st, 2016, 3:00pm GMT
Condition: Brain Neoplasms, Adult, Malignant
Intervention: Radiation: Stereotactic Radiosurgery
Sponsor: University of Texas Southwestern Medical Center
Recruiting -
Tumor Related Epilepsy
Posted: December 24th, 2015, 3:00pm GMT
Conditions: Epilepsy; Cancer; Brain Neoplasm
Intervention:
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting -
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer
Posted: December 18th, 2015, 3:00pm GMT
Conditions: Extensive Stage Small Cell Lung Carcinoma; Limited Stage Small Cell Lung Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Other: Cognitive Assessment; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: NRG Oncology; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting -
Neurobehavioral Outcomes and Quality of Life in Pediatric Patients With Brain or Head/Neck Tumors Receiving Proton or Photon Radiotherapy
Posted: November 20th, 2015, 3:00pm GMT
Condition: Brain Tumor
Intervention: Radiation: standard adjuvant local radiation therapy or cranial radiation therapy
Sponsor: Chang Gung Memorial Hospital
Recruiting -
Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor
Posted: October 15th, 2015, 2:00pm GMT
Condition: Brain Metastases
Intervention: Radiation: brain metastatic patients
Sponsor: Istituto Clinico Humanitas
Recruiting -
Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Posted: October 15th, 2015, 2:00pm GMT
Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Carcinoma, Ductal, Breast; Melanoma; Solid Tumors; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas
Intervention: Drug: Larotrectinib LOXO-101
Sponsors: Bayer; Loxo Oncology, Inc.
Recruiting -
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Posted: September 30th, 2015, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Refractory Tumor; Recurrent Tumor; CNS Malignancies
Intervention: Drug: Ramucirumab
Sponsors: Eli Lilly and Company; Children's Oncology Group
Recruiting -
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
Posted: May 13th, 2015, 2:00pm GMT
Conditions: Brain Tumor, Recurrent; Brain Tumor, Refractory
Intervention: Biological: HER2-specific T cells
Sponsors: Baylor College of Medicine; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine; Texas Children's Hospital
Recruiting -
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Posted: March 18th, 2015, 2:00pm GMT
Conditions: Metastatic Brain Tumor; Primary Brain Tumor
Intervention: Device: NeuroBlate System
Sponsor: Monteris Medical
Recruiting -
D2C7 for Adult Patients With Recurrent Malignant Glioma
Posted: December 1st, 2014, 3:00pm GMT
Conditions: Malignant Glioma; Brain Tumor, Recurrent
Intervention: Drug: D2C7-IT
Sponsor: Darell D. Bigner, MD, PhD
Recruiting -
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Posted: July 1st, 2014, 2:00pm GMT
Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: photon beam radiation therapy; Radiation: proton beam radiation therapy; Drug: temozolomide; Other: laboratory biomarker analysis
Sponsors: NRG Oncology; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting -
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
Posted: April 2nd, 2014, 2:00pm GMT
Conditions: Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Oligodendroglioma; Gliosarcoma; Mixed Glioma; Recurrent Adult Brain Neoplasm; Recurrent Glioblastoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Lapatinib Ditosylate; Other: Pharmacological Study; Procedure: Therapeutic Conventional Surgery
Sponsor: National Cancer Institute (NCI)
Recruiting -
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
Posted: July 3rd, 2013, 2:00pm GMT
Condition: Tumors Metastatic to Brain
Interventions: Radiation: radiosurgery; Procedure: therapeutic conventional surgery; Procedure: quality-of-life assessment
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting -
Study of DC Vaccination Against Glioblastoma
Posted: March 30th, 2012, 2:00pm GMT
Conditions: Glioma; Glioblastoma Multiforme; Neoplasms
Interventions: Procedure: Surgery; Drug: Chemotherapy; Radiation: Radiotherapy; Biological: DC vaccination; Drug: blank placebo
Sponsors: Huashan Hospital; Fudan University
Recruiting -
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Posted: January 6th, 2012, 3:00pm GMT
Conditions: Ewing's Family Tumors; Renal Tumors; Hepatoblastoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Primary Malignant Brain Neoplasms; Retinoblastoma; Medulloblastoma; Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET); Atypical Teratoid/Rhabdoid Tumor (AT/RT); CNS Tumors; Germ Cell Tumors
Interventions: Drug: Ifosfamide; Drug: Etoposide; Drug: Mesna; Biological: G-CSF; Drug: Busulfan; Drug: Melphalan; Drug: Thiotepa; Biological: Autologous stem cell infusion; Radiation: Radiation; Drug: Carboplatin; Drug: Paclitaxel; Procedure: Leukapheresis; Drug: Anti-seizure prophylaxis; Drug: Ursodiol
Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting -
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Posted: December 19th, 2011, 3:00pm GMT
Condition: Breast Cancer
Interventions: Drug: HKI-272; Procedure: Surgical Resection; Drug: Capecitabine; Drug: Ado-Trastuzumab Emtansine
Sponsors: Dana-Farber Cancer Institute; Translational Breast Cancer Research Consortium; Puma Biotechnology, Inc.
Recruiting -
Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases
Posted: October 3rd, 2011, 2:00pm GMT
Conditions: Brain Metastasis; Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting -
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Posted: March 18th, 2010, 2:00pm GMT
Conditions: Low Grade Glioma; Recurrent Childhood Pilocytic Astrocytoma; Recurrent Neurofibromatosis Type 1; Recurrent Visual Pathway Glioma; Refractory Neurofibromatosis Type 1; Refractory Visual Pathway Glioma
Interventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Selumetinib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Posted: April 23rd, 2009, 2:00pm GMT
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: concomitant temozolomide (TMZ); Radiation: radiotherapy; Drug: procarbazine; Drug: adjuvant temozolomide (TMZ); Drug: CCNU; Drug: vincristine
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); European Organisation for Research and Treatment Center (EORTC); Canadian Cancer Trials Group
Recruiting -
Florida Center for Brain Tumor Research
Posted: December 18th, 2008, 3:00pm GMT
Condition: Brain Tumors
Intervention: Procedure: Tissue Bank
Sponsor: University of Florida
Recruiting -
Pituitary Tumor Surveillance: Pathogenic Correlation
Posted: January 23rd, 2008, 3:00pm GMT
Condition: Pituitary Tumor
Intervention:
Sponsor: Cedars-Sinai Medical Center
Recruiting -
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum
Posted: September 23rd, 2002, 2:00pm GMT
Conditions: Xeroderma Pigmentosum; Melanoma; Squamous Cell Carcinoma; Basal Cell Carcinoma; Skin Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting